Blackstone and its BioMed Realty affiliate have paid $250M to acquire three Kendall Square life sciences buildings. The deal ...

Editas Medicine Inc.股价跌至52周新低，触及1.27美元，较52周高点11.58美元大幅下跌89%。这家生物科技公司目前市值仅为1.06亿美元，尽管其资产负债表健康，现金多于债务，但仍面临市场逆风。这一最新价格较之前的估值显著下降，反映出过去一年88%的急剧下跌。投资者对公司前景持谨慎态度，导致持续抛售，最终达到这一新低。根据 InvestingPro ...

To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery ...

Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective trimmed by Evercore ISI from $7.00 to $5.00 in a report ...

A Cambridge-based biotechnology company announced Thursday its plans to lay off about 65% of its workforce over the next ...

Fintel reports that on December 16, 2024, JP Morgan downgraded their outlook for Editas Medicine (NasdaqGS:EDIT) from Neutral ...

On Friday, Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.44 which represents a decrease of $-0.45 or -23.81% from the prior close of $1.89. The stock opened at $1.75 and touched ...

Here are today's Five Things You Need to Know today in Boston business news, including Editas job cuts, CVS shares plunge, Moderna's name in the sky, the Boston tea party and the best birthday gift ...

Chardan Capital reiterated their neutral rating on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research note ...

Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target ...

Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.